Overview
Loblaw Q3 revenue grows 4.6%, meeting analyst expectations
Adjusted EPS for Q3 beats analyst estimates, reflecting strong operational performance
Company completes four-for-one stock split, enhancing share liquidity
Outlook
Loblaw expects full-year adjusted EPS growth to increase to low double-digits
Company plans C$1.9 bln net capital investments in 2025
Loblaw to return capital via share repurchases
Result Drivers
VALUE OFFERINGS - Everyday value offerings and personalized loyalty rewards drove higher customer engagement, boosting sales
NEW STORE OPENINGS - Opening of 19 new stores, including Maxi and NoFrills, expanded discount options and increased customer traffic
SPECIALTY DRUG GROWTH - Specialty drug growth in Drug Retail segment contributed to strong results
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Meet
C$19.40 bln
C$19.40 bln (8 Analysts)
Q3 Adjusted EPS
Beat
C$0.69
C$0.68 (8 Analysts)
Q3 EPS
C$0.66
Q3 Adjusted Net Income
Beat
C$828 mln
C$815.09 mln (3 Analysts)
Q3 Net Income
C$794 mln
Q3 Adjusted EBITDA
Beat
C$2.22 bln
C$2.19 bln (7 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food retail & distribution peer group is "buy"
Wall Street's median 12-month price target for Loblaw Companies Ltd is C$61.13, about 7.5% above its November 11 closing price of C$56.53
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 22 three months ago
Press Release: ID:nCNW9xKHba
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)